Dr. Thomas Powles explains standard treatment for metastatic urothelial cancer
Treatment following progression on chemotherapy and an immune checkpoint inhibitor remains an unmet medical need.
Treatment following progression on chemotherapy and an immune checkpoint inhibitor remains an unmet medical need.
Treatment with the intravesical gemcitabine delivery system TAR-200 led to complete responses in over 80% of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer, according to…
Extended lymph node dissection during radical cystectomy offered no additional overall survival or disease-free survival benefit vs standard lymph node dissection.
Treatment with apalutamide and androgen deprivation therapy led to a 2-year biochemical recurrence-free survival rate of 100% in patients with high-risk, post-prostatectomy prostate cancer.
The novel oncolytic immunotherapy cretostimogene grenadenorepvec induced complete responses (CRs) in three-fourths of patients with BCG unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, according…
Neal D. Shore, MD, shares what he’s most looking forward to at this year’s American Urological Association Annual Meeting.
UroViu’s portable and versatile disposable cystoscopy platform delivers consistent performance, on par with reusable scopes, advancing clinical care, and limiting disposable waste. The benefit of…
“[This] shows a different approach for detecting circulating tumor DNA in bladder cancer patients, and it opens up the possibility for other biorepositories that have…
Investigators will begin setting up the TRANSFORM trial in spring 2024, with study recruitment set to begin later in the year
The test, which was launched in Canada in September 2023, is available through Nanostics’ accredited laboratory in Edmonton, Alberta.
“We felt that it was important to again address this topic because we have received numerous questions regarding the correct use of this code and…